CLOVClover Health Investments, Corp.
Is the price fair?
Priced for a lot of growth. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~14% a year FCF growth. The price already bakes in strong, sustained growth.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What CLOV's price assumes
Today's price asks for 14% free cash flow growth a year; over the last three years Clover Health Investments, Corp. delivered 55%, less than the record.
Price / sales · no trailing P/E on file: measured against sales instead
- Free cash flow yield
- 2.7%
Free cash flow yield · Healthcare Plans median 6.5%
- Growth the price implies
- +14%
Growth the price implies · The price pays for +14% free cash flow growth a year for a decade; the business has delivered +55% a year over the last three.
- Price / book
- 8.89
Price / book · today's price, fiscal year to Dec 31, 2025
Details›
- Price / booktoday's price, fiscal year to Dec 31, 2025
- 8.89
- EV / EBIToperating margin −0.74%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, fiscal year to Dec 31, 2025
- 1.37
- Free cash flow, trailing twelve months
- $74M
- Market capitalisation
- $2.74B
- 3-year free cash flow growth
- +55%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.